Dr Reddy’s Sees Tocilizumab Clear Phase I
Indian Firm’s Biosimilar Rival To Actemra/RoActemra Moves Into Phase III Trials
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
You may also be interested in...
At the European Society of Rheumatology conference currently taking place in Milan, Italy, Celltrion unveiled progress for its proposed biosimilar to Roche’s Actemra/RoActemra (tocilizumab).
Bio-Thera Solutions has claimed the first approval for a biosimilar rival to Actemra/RoActemra anywhere in the world, after receiving a nod from China’s NMPA for its BAT1806 tocilizumab candidate.
Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.